Where Do We Stand in the Management of Oligometastatic Prostate Cancer? A Comprehensive Review

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2022 Apr 23

PMID 35454924

Authors

Gomez Rivas Juan

Fernandez Hernandez Laura

Puente Vazquez Javier

Vidal Casinello Natalia

Galante Romo M Isabel

Redondo Gonzalez Enrique

Senovilla Perez Jose Luis

Abad Lopez Pablo

Sanmamed Salgado Noelia

Vives Dilme Roser

Moreno-Sierra Jesus

Affiliations

Soon will be listed here.

Abstract

Oligometastatic prostate cancer (OMPC) is an intermediate state between localised disease and widespread metastases that includes a spectrum of disease biology and clinical behaviours. This narrative review will cover the current OMPC scenario. We conducted comprehensive English language literature research for original and review articles using the Medline database and grey literature through December 2021. OMPC is a unique clinical state with inherently more indolent tumour biology susceptible to multidisciplinary treatment (MDT). With the development of new imaging techniques, patients with OMPC are likely to be identified at an earlier stage, and the paradigm for treatment is shifting towards a more aggressive approach to treating potentially curable patients. Multimodal management is necessary to improve patient outcomes due to the combination of available therapies, such as local therapy of primary tumour, metastasis directed therapy or systemic therapy, to reduce tumour load and prevent further disease progression. Additional prospective data are needed to select patients most likely to benefit from a given therapeutic approach.

Citing Articles

A Personalized Approach for Oligometastatic Prostate Cancer: Current Understanding and Future Directions.

Alerasool P, Zhou S, Miller E, Anker J, Tsao B, Kyprianou N Cancers (Basel). 2025; 17(1).

PMID: 39796774 PMC: 11720581. DOI: 10.3390/cancers17010147.

Improved survival of patients with newly diagnosed oligometastatic prostate cancer through intensified multimodal treatment.

Schutz V, Nessler C, Duensing A, Zschabitz S, Jager D, Debus J Front Oncol. 2024; 14:1475914.

PMID: 39720562 PMC: 11666478. DOI: 10.3389/fonc.2024.1475914.

The therapeutic use of 177 Lu-PSMA-617 radioligand therapy in prostate cancer treatment: a review of literature and ongoing trials.

Konopnicki A, Zaliznyak M, Roy M, Jana B Discov Oncol. 2024; 15(1):791.

PMID: 39692806 PMC: 11655789. DOI: 10.1007/s12672-024-01680-z.

Predictive Models for Assessing Patients' Response to Treatment in Metastatic Prostate Cancer: A Systematic Review.

Lawlor A, Lin C, Rivas J, Ibanez L, Abad Lopez P, Willemse P Eur Urol Open Sci. 2024; 63:126-135.

PMID: 38596781 PMC: 11001619. DOI: 10.1016/j.euros.2024.03.012.

Progress in Oligometastatic Prostate Cancer: Emerging Imaging Innovations and Therapeutic Approaches.

Oka R, Utsumi T, Noro T, Suzuki Y, Iijima S, Sugizaki Y Cancers (Basel). 2024; 16(3).

PMID: 38339259 PMC: 10854639. DOI: 10.3390/cancers16030507.

References

Francini E, Gray K, Xie W, Shaw G, Valenca L, Bernard B . Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC). Prostate. 2018; 78(12):889-895. PMC: 6171350. DOI: 10.1002/pros.23645. View

Prive B, Peters S, Muselaers C, van Oort I, Janssen M, Sedelaar J . Lutetium-177-PSMA-617 in Low-Volume Hormone-Sensitive Metastatic Prostate Cancer: A Prospective Pilot Study. Clin Cancer Res. 2021; 27(13):3595-3601. DOI: 10.1158/1078-0432.CCR-20-4298. View

Le D, Uram J, Wang H, Bartlett B, Kemberling H, Eyring A . PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015; 372(26):2509-20. PMC: 4481136. DOI: 10.1056/NEJMoa1500596. View

Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev B . Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. Lancet Oncol. 2019; 20(5):686-700. DOI: 10.1016/S1470-2045(19)30082-8. View

Larbi A, Dallaudiere B, Pasoglou V, Padhani A, Michoux N, Vande Berg B . Whole body MRI (WB-MRI) assessment of metastatic spread in prostate cancer: Therapeutic perspectives on targeted management of oligometastatic disease. Prostate. 2016; 76(11):1024-33. DOI: 10.1002/pros.23196. View

Vale C, Burdett S, Rydzewska L, Albiges L, Clarke N, Fisher D . Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data. Lancet Oncol. 2016; 17(2):243-256. PMC: 4737894. DOI: 10.1016/S1470-2045(15)00489-1. View

Soloway M, Hardeman S, Hickey D, Raymond J, Todd B, Soloway S . Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer. 1988; 61(1):195-202. DOI: 10.1002/1097-0142(19880101)61:1<195::aid-cncr2820610133>3.0.co;2-y. View

Bray F, Ferlay J, Soerjomataram I, Siegel R, Torre L, Jemal A . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6):394-424. DOI: 10.3322/caac.21492. View

Ost P, Reynders D, Decaestecker K, Fonteyne V, Lumen N, De Bruycker A . Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial. J Clin Oncol. 2017; 36(5):446-453. DOI: 10.1200/JCO.2017.75.4853. View

10.

Ost P, Jereczek-Fossa B, van As N, Zilli T, Muacevic A, Olivier K . Progression-free Survival Following Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Treatment-naive Recurrence: A Multi-institutional Analysis. Eur Urol. 2015; 69(1):9-12. DOI: 10.1016/j.eururo.2015.07.004. View

11.

Hofman M, Lawrentschuk N, Francis R, Tang C, Vela I, Thomas P . Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet. 2020; 395(10231):1208-1216. DOI: 10.1016/S0140-6736(20)30314-7. View

12.

Sokolova A, Cheng H . Genetic Testing in Prostate Cancer. Curr Oncol Rep. 2020; 22(1):5. PMC: 10832578. DOI: 10.1007/s11912-020-0863-6. View

13.

Evans J, Jethwa K, Ost P, Williams S, Kwon E, Lowe V . Prostate cancer-specific PET radiotracers: A review on the clinical utility in recurrent disease. Pract Radiat Oncol. 2017; 8(1):28-39. DOI: 10.1016/j.prro.2017.07.011. View

14.

Heidenreich A, Fossati N, Pfister D, Suardi N, Montorsi F, Shariat S . Cytoreductive Radical Prostatectomy in Men with Prostate Cancer and Skeletal Metastases. Eur Urol Oncol. 2019; 1(1):46-53. DOI: 10.1016/j.euo.2018.03.002. View

15.

Wang L, Paller C, Hong H, De Felice A, Alexander G, Brawley O . Comparison of Systemic Treatments for Metastatic Castration-Sensitive Prostate Cancer: A Systematic Review and Network Meta-analysis. JAMA Oncol. 2021; 7(3):412-420. PMC: 7809610. DOI: 10.1001/jamaoncol.2020.6973. View

16.

Ost P, Bossi A, Decaestecker K, De Meerleer G, Giannarini G, Karnes R . Metastasis-directed therapy of regional and distant recurrences after curative treatment of prostate cancer: a systematic review of the literature. Eur Urol. 2014; 67(5):852-63. DOI: 10.1016/j.eururo.2014.09.004. View

17.

Kyriakopoulos C, Chen Y, Carducci M, Liu G, Jarrard D, Hahn N . Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial. J Clin Oncol. 2018; 36(11):1080-1087. PMC: 5891129. DOI: 10.1200/JCO.2017.75.3657. View

18.

Davis I, Martin A, Stockler M, Begbie S, Chi K, Chowdhury S . Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer. N Engl J Med. 2019; 381(2):121-131. DOI: 10.1056/NEJMoa1903835. View

19.

Jang W, Kim M, Jeong W, Chang K, Cho K, Ham W . Does robot-assisted radical prostatectomy benefit patients with prostate cancer and bone oligometastases?. BJU Int. 2017; 121(2):225-231. DOI: 10.1111/bju.13992. View

20.

Sooriakumaran P, Wilson C, Rombach I, Hassanali N, Aning J, Lamb A . Feasibility and safety of radical prostatectomy for oligo-metastatic prostate cancer: the Testing Radical prostatectomy in men with prostate cancer and oligo-Metastases to the bone (TRoMbone) trial. BJU Int. 2021; 130(1):43-53. DOI: 10.1111/bju.15669. View